SEC EDGARAUG 251 min read$CBLL

Manni Joseph S. sold $33K of CBLL

Manni Joseph S. (Chief Revenue Officer) sold 1,361 shares of Ceribell, Inc. (CBLL) at $24.02 on 2026-08-21.

Original reporting

SEC EDGAR · Manni Joseph S.

Published Aug 25, 2026, 11:29 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 25, 2026, 11:32 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CBLL

Neutral

high confidence

Mentioned

$CBLL

Relevance

3/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBLLNeutralLow

Why it matters

The sale is modest and does not indicate a shift in executive confidence

Market read

Routine insider sale with minimal market impact

What to watch

Potential upcoming dilution or secondary offering not disclosed

Relevance 3/10Novelty 3/10Timing: filed post‑market on 2026-08-25

Background

Form 4 filings disclose insider transactions; traders monitor for material changes

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBLLNeutralHigh confidence

Context

Chief Revenue Officer sold 1,361 shares for $32,691.22 on 2026-08-21

Expected impact

No significant impact expected

Evidence & confidence

Sale size is small relative to float and disclosed via Form 4; market typically views such routine sales as neutral

Market effects

Sector

None; Ceribell operates in medical diagnostics niche

Regional

No regional effect

Global

Limited to investors tracking insider activity

Counterpoint

What could challenge this read

If insider sells signal concerns, could prompt short interest

Key entities

Officer
Manni Joseph S.
Chief Revenue Officer of Ceribell, Inc.

Read at source ← All news

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 10

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min

AUG 10

$CBLLMedAI 8/10

Ceribell Secures FDA Clearance For Advanced EEG AI Enhancements

Ceribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.

rttnews.com4 min

AUG 3

$CBLLMedAI 8/10

CeriBell stock rises after securing Medicare payment approval

CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.

investing.com3 min

MAY 26

$CBLLMed

Manni Joseph S. sold $25K of CBLL

Manni Joseph S. (Chief Revenue Officer) sold 1,378 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.

SEC EDGAR2 min

SEP 4

$ILMNMedAI 8/10

Meister Keith A. sold $57.2M of ILMN (indirect holdings)

Meister Keith A. sold 263,560 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $217.03 ($213.20–$221.55, $57.20M total) across 12 trades over 2026-09-02 to 2026-09-04.

SEC EDGAR1 min